General Information of Drug (ID: DM6ZHTV)

Drug Name
CAR-CLD18 T cell Drug Info
Indication
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Clinical trial [1]
Pancreatic cancer 2C10 Clinical trial [1]
Cross-matching ID
TTD Drug ID
DM6ZHTV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Drug(s) Targeting Claudin-18 (CLDN18)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Claudiximab DMPQR1D Gastric adenocarcinoma 2B72 Phase 3 [2]
Zolbetuximab DM5ST9Z Esophagogastric junction neoplasm 2B71 Phase 3 [3]
CT-041 DM5XX06 Gastric cancer 2B72 Phase 1/2 [4]
RC118 DMU25QT Aggressive cancer 2A00-2F9Z Phase 1/2 [5]
AMG 910 DMCG7XL Esophagogastric junction neoplasm 2B71 Phase 1 [6]
TST001 DMZ9EMO Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
SKB315 DMI0JT4 Aggressive cancer 2A00-2F9Z Phase 1 [8]
ASP2138 DM96QLF Stomach cancer 2B72 Phase 1 [9]
BNT212 DM27NTT Aggressive cancer 2A00-2F9Z Preclinical [10]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Claudin-18 (CLDN18) TT6PKBX CLD18_HUMAN CAR-T-Cell-Therapy [1]

References

1 ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
2 Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2014 Feb 1;134(3):731-9.
3 FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021 May;32(5):609-619.
4 Clinical pipeline report, company report or official report of CARSGEN
5 ClinicalTrials.gov (NCT05205850) An Open, Multi-center Phase I/IIa Clinical Study of RC118 for Injection in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors With Positive Expression of Claudin 18.2. U.S.National Institutes of Health.
6 Clinical pipeline report, company report or official report of Amgen.
7 Clinical pipeline report, company report or official report of Transcenta.
8 Clinical pipeline report, company report or official report of Klus Pharma
9 ClinicalTrials.gov (NCT05365581) A Phase 1/1b Study of ASP2138 in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression. U.S.National Institutes of Health.
10 Clinical pipeline report, company report or official report of Biontech